Highest-materiality recent filing
Tenaya Therapeutics reports Q2 2026 net loss of $43.4M; positive interim data for TN-201 and TN-401
Net loss of $43.4M ($0.20 loss per share) vs $23.3M loss in Q2 2025; includes $21.8M impairment charge from GMMC lease termination.
Tenaya Therapeutics terminates lease for GMMC Facility; forfeits $1.75M deposit
Terminated lease for 94,046 sq ft GMMC Facility in Union City, CA; original expiry July 2031, now ends Aug 31, 2026.
Tenaya Therapeutics appoints Eric Hyllengren as CFO effective July 13, 2026
Eric Hyllengren joins as CFO; previously CFO at Zura Bio, CFO/COO at Atara Biotherapeutics.
Tenaya shareholders approve amended equity plan adding 6.5M shares, elect directors
Shareholders approved amended 2021 Equity Incentive Plan with one-time increase of 6,509,966 shares (~3% of outstanding).
Tenaya reports Q1 net loss $19.3M, cash $80.9M; Alnylam deal; TN-201/401 data expected Q2 2026
Net loss $19.3M ($0.09/share) vs $26.9M ($0.24/share) in Q1 2025; cash $80.9M as of Mar 31, 2026.
Tenaya reports FY2025 net loss of $90.6M; cash runway into H2 2027
Net loss $90.6M ($0.59/share) for FY2025 vs $111.1M ($1.31) in FY2024; Q4 net loss $20.2M.
Tenaya and Alnylam collaborate to discover/validate up to 15 cardiovascular gene targets; 24-month research term.
Tenaya receives Nasdaq bid price deficiency notice; 180-day cure period to July 27, 2026
Nasdaq notified Tenaya on Jan 28, 2026 that stock failed to meet $1.00 minimum bid price for 30 consecutive business days through Jan 27, 2026.
Director David Goeddel resigns from Tenaya board effective Jan 26, 2026
David Goeddel submitted resignation from the Board and all committees on Dec 31, 2025. Effective Jan 26, 2026.
Tenaya Therapeutics prices $60M public offering of 50M units at $1.20/unit; warrants at $1.50
Gross proceeds ~$60M from 50M units, each unit = 1 share + 1 warrant (5-yr, $1.50 exercise).
FDA lifts clinical hold on TN-201; TN-401 shows positive interim data in ARVC patients
FDA removed clinical hold on MyPEAK-1 trial for TN-201 gene therapy; protocol amendments implemented, dosing to resume.
Tenaya reports Q3 net loss $20.3M; FDA places clinical hold on TN-201 MyPEAK-1 trial
Net loss $20.3M ($0.12/share) vs $25.6M ($0.30) in Q3 2024; cash $56.3M, sufficient into H2 2026.
FDA places clinical hold on Tenaya's Phase 1b/2a TN-201 trial due to protocol amendment request
FDA requests protocol amendment to standardize patient monitoring and immunosuppression management across trial sites.
Tenaya Therapeutics Q2 net loss $23.3M; cash runway into H2 2026; TN-201/401 data Q4 2025
Net loss $23.3M ($0.14 loss per share) vs $29.4M ($0.34) in Q2 2024.
Tenaya Therapeutics shareholders elect all three Class I directors and ratify Deloitte as auditor
David Goeddel, Ph.D. elected with 80,444,762 votes for, 8,262,596 withheld.
Tenaya Therapeutics reports Q1 net loss of $26.9M; cash runway into H2 2026
Q1 2025 net loss $26.9M ($0.24 loss per share) vs $32.2M ($0.40 loss) in Q1 2024.
Tenaya receives Nasdaq bid price deficiency notice; must regain compliance by Oct 13, 2025
Closing bid price of TNYA common stock below $1.00 for 30 consecutive business days through April 12, 2025.
Tenaya Therapeutics approves restructuring; workforce reduction extends cash runway to H2 2026
Restructuring focuses resources on TN-201 (MyPEAK-1) and TN-401 (RIDGE-1) gene therapy trials.
Net loss of $23.8M ($0.28 per share) for Q4 2024; full-year net loss $111.1M ($1.31 per share).
Tenaya Therapeutics prices $52.5M public offering of units with warrants
Priced 75M units at $0.70/unit; gross proceeds ~$52.5M before expenses.
Tenaya appoints interim PAO and reprices CEO underwater options to $1.21
Tomohiro Higa appointed Interim Principal Accounting Officer effective Feb 6, 2025; he remains SVP Finance.
Tenaya Therapeutics reprices underwater employee stock options to $1.21 per share
Repriced ~4.1M shares of underwater options with original exercise prices $3.06-$21.01 to $1.21 per share.
Tenaya Therapeutics' SVP & Interim PAO Chihiro Saito resigns effective Dec 16, 2024
Chihiro Saito resigned as SVP, Accounting and Financial Operations and Interim Principal Accounting Officer.
Tenaya's TN-201 shows robust cardiac transduction, increasing mRNA and protein in 3 HCM patients
TN-201 well tolerated at 3E13 vg/kg; no cardiac toxicities or TMA; liver enzyme elevations managed with corticosteroids.
Net loss of $25.6M ($0.30 per share) vs $29.1M ($0.39) in Q3 2023.
Tenaya Therapeutics adopts 2024 Inducement Plan, reclassifies director to balance board
Karah Parschauer reclassified from Class I to Class II director to balance board classes (3 per class).
Tenaya Q2 net loss $29.4M; cash $99.3M; TN-201 gets FDA rare pediatric designation; CFO departs
Net loss $29.4M ($0.34/share) vs $33.3M ($0.45) in Q2 2023; R&D expenses $22.6M.
Tenaya Therapeutics CFO Leone Patterson resigning effective Aug 14, 2024
Leone Patterson, Chief Financial and Business Officer, resigns to pursue another opportunity; will remain until August 14, 2024.
Tenaya Therapeutics Director Jin-Long Chen Resigns
Jin-Long Chen resigned as a director of Tenaya Therapeutics on June 25, 2024.
Tenaya stockholders elect three Class III directors, ratify Deloitte as auditor
Faraz Ali elected with 60,262,398 votes for, 157,949 withheld; broker non-votes 10,386,279.
Tenaya Q1 net loss $32.2M; cuts 22% workforce; cash runway into H2 2025
Net loss $32.2M ($0.40/share) vs $31.7M ($0.43) in Q1 2023; R&D spend $25.1M.
Tenaya reports Q4 net loss $29.9M; cash $104.6M; TN-201 data and TN-401 dosing expected H2 2024
Net loss $29.9M ($0.40/sh) Q4 2023; full year net loss $124.1M ($1.68/sh).
Gross proceeds expected ~$50M from 8,888,890 common shares at $4.50 and 2,222,271 pre-funded warrants at $4.499.
Tenaya Q3 net loss $29.1M; first patient dosed in TN-201 HCM trial
Q3 net loss $29.1M ($0.39/share); R&D $23.1M, G&A $7.8M; cash $128.1M into H1 2025.
Tenaya Q2 net loss $33.3M; TN-201 first patient dosing on track for Q3 2023
Cash and investments $151.6M; runway into first half 2025.
Tenaya amends severance plan: CEO gets 12-18 months salary; shareholders approve officer exculpation
CEO Faraz Ali: non-CIC severance 12 months base; CIC severance 18 months base + 150% target bonus; COBRA up to 18 months.
Tenaya reports Q1 net loss $31.7M; cash $173.6M; TN-201 gets FDA Fast Track
Cash, equivalents and marketable securities $173.6M as of March 31, 2023; runway into H1 2025.
Tenaya Therapeutics adopts amended bylaws with enhanced stockholder nomination procedures
Enhanced disclosure requirements for stockholder director nominations and business proposals.
Tenaya says SVB exposure minimal; loss immaterial
Maintains operating accounts at SVB with minimal balance relative to total cash and investments.
Tenaya Therapeutics FY2022 net loss $123.7M; TN-201 IND cleared, Phase 1b Q3 2023
Net loss of $33.5M ($0.61/share) in Q4 2022 and $123.7M ($2.76/share) in FY2022.
Tenaya Therapeutics appoints Amy Burroughs to board; Eli Casdin resigns
Eli Casdin resigned from board and audit committee effective Dec 5, 2022; no disagreement with company.
Tenaya Therapeutics prices public offering of ~28.85M shares/warrants for ~$75M gross proceeds
Priced public offering of 22,613,307 common shares at $2.60 and 6,236,693 pre-funded warrants at $2.599 per warrant.
Tenaya Therapeutics Q3 net loss $30.7M; cash runway extended to mid-2024
Cash and investments $149.5M as of Sept 30; funds expected to support operations to mid-2024.
Tenaya Therapeutics Q2 2022 net loss $28.4M; cash $180.9M; IND submissions on track
Net loss $28.4M ($0.69 per share); R&D expense $20.9M; G&A expense $7.7M.
Tenaya Therapeutics enters $75M at-the-market equity sales agreement with SVB Securities
Aggregate sales proceeds up to $75M from common stock sold through ATM program.
Tenaya Therapeutics reports stockholder votes from 2022 annual meeting
Four Class I directors elected: David Goeddel (34,063,079 for), Karah Parschauer (34,833,578), Jeffrey Walsh (34,112,810), R. Sanders Williams (34,135,556); 829,857 broker non-votes each.
Tenaya Q1 net loss $31.1M; TN-201 gets EU orphan designation, IND filings on track
Cash, equivalents and marketable securities of $213.5M at March 31; runway into H2 2023.
Tenaya reports FY2021 net loss $72.7M; cash runway into H2 2023; three programs advancing
Cash, equivalents and investments $251.3M at Dec 31, 2021 vs $128.5M year-end 2020; runway to H2 2023.
Tenaya Therapeutics appoints Karah Parschauer to Board and Joanna Auch as SVP of People and Culture
Board expanded to 10 members; Karah Parschauer appointed as Class I director and audit committee member.
Tenaya Therapeutics appoints Dr. June Lee to board; Dr. JeenJoo Kang resigns
Dr. June Lee appointed as Class III director, term expiring at 2024 annual meeting.
Effective February 6, 2025, Mr. Tomohiro Higa, Senior Vice President, Finance, of Tenaya Therapeutics, Inc. (the “Company”), will assume the role of Interim Principal Accounting Officer (“Interim PAO”) for the Company in addition to his role as Senior Vice President, Finance.
Ms. Chihiro Saito, Tenaya’s Senior Vice President, Accounting and Financial Operations, will assume the role of Interim PAO for the Company
Faraz Ali, Chief Executive Officer of Tenaya, will become Interim PFO in addition to his role as Chief Executive Officer.
Effective August 14, 2024, upon Ms. Leone Patterson ceasing to be the Chief Financial and Business Officer, Principal Financial Officer (PFO) and Principal Accounting Officer (PAO) for Tenaya
On July 19, 2024, Leone Patterson, Chief Financial and Business Officer (“CFBO”) of Tenaya Therapeutics, Inc. (“Tenaya” or the “Company”), advised Tenaya that she was resigning from her role as CFBO, Principal Financial Officer and Principal Accounting Officer to pursue another opportunity.
On June 25, 2024, Jin-Long Chen submitted his resignation as a director of Tenaya Therapeutics, Inc.
On December 5, 2022, Eli Casdin submitted his resignation as a director of Tenaya Therapeutics, Inc. (the “Company”) and as a member of the Company’s Audit Committee (the “Audit Committee”).
On December 5, 2022, the Board appointed Amy Burroughs, to serve as a Class II director, with a term expiring at the Company’s 2023 annual meeting of stockholders.
appointed Karah Parschauer to the Board and as a member of the audit committee of the Board
On November 17, 2021, JeenJoo Kang, Ph.D., submitted her resignation as a director of Tenaya Therapeutics, Inc.
On November 19, 2021, the Board appointed June Lee, M.D., to serve as a Class III director
Max materiality 0.85 · Median 0.60 · Most common event earnings